Encircling the regions of the pharmacogenomic landscape that determine drug response
The integration of large-scale drug sensitivity screens and genome-wide experiments is changing the field of pharmacogenomics, revealing molecular determinants of drug response without the need for a priori, hypothesis-driven assumptions about drug action. In particular, transcriptomic signatures of drug sensitivity may guide drug repositioning, the discovery of synergistic drug combinations and suggest new therapeutic biomarkers. However, the inherent complexity of transcriptomic signatures, with thousands of genes differentially expressed, makes them hard to interpret, giving poor mechanistic insights and hampering translation to the clinics. Here we show how network biology can help simplify transcriptomic drug signatures, filtering out irrelevant genes, accounting for tissue-specific biases and ultimately yielding functionally-coherent, less noisy drug modules. We successfully analyzed 170 drugs tested in 637 cancer cell lines, proving a broad applicability of our approach and evincing an intimate relationship between modules gene expression levels and drugs mechanisms of action. Further, we have characterized multiple aspects of our transcriptomic modules. As a result, the drugs included in this study are now annotated well beyond the reductionist (target-centered) view.\n\nAuthor SummaryLarge scale pharmacogenomics studies performed with hundreds of cell lines offer a means to link the molecular features of the cells to their response to drug treatments. Unfortunately, simple drug-gene correlations are usually not enough to consistently identify what gene expression patterns will determine drug sensitivity, as the tissue of origin of the cells, together with the expression of e.g. membrane transporters can greatly confound the analysis. To ameliorate these biases, we have devised a network-based strategy that selects genes that are both well correlated to drug response and closeby in the human protein interaction network. Reassuringly, we have confirmed that our identified drug sensitivity modules are tightly connected to the mechanisms of action of the drugs. Moreover, while our modules have no more than 100 genes, they retain the predictive power of the much larger gene signatures that are typically obtained by drug-gene correlations alone. Here, we release the characteristic modules for almost 200 drugs, in a format that is suitable for downstream bioinformatics analyses such as gene-set enrichment analysis.